Sandra Garcês

Sandra Garcês

Auto-generated profile, based on publicly available information

Sandra Garcês

Gulbenkian Institute of Science, Portugal, Rua da Quinta Grande, 6, 2780-156 Oeiras, Portugal; Garcia de Orta Hospital, Portugal, Department of Rheumatology; HGO Research Center, Av. Torrado da Silva, 2801-951 Almada, Portugal

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
SGSandra Garcês
Sandra Garcês
JDJocelyne Demengeot
Jocelyne Demengeot
EBElizabeth Benito-Garcia
Elizabeth Benito-Garcia
Immunogenicity of aTNFs is one of the mechanisms behind treatment failure. To assess the effect of anti-drug antibodies (ADA) on drug response to infliximab, adalimumab and etanercept, and the effect of immunosuppression on ADA detection, in patients with Rheumatoid Arthritis, Spondyloarthritis, Psoriasis and Inflammatory Bowel Diseases. PubMed, EMBASE, Cochrane databases, article reference lists (through August 19 2012). Out of 2082 studies, 17 were used in the meta-analysis (1RCT; 16 observational studies). Two reviewers extracted data. Risk ratios (RR), 95% CI, using random-effect models, sensitivity analysis, meta-regressions and Egger's test were calculated. Of 865 patients, ADA against infliximab or adalimumab reduced drug response rate by 68% (RR=0.68, 95% CI=0.12 to 0.36), an effect attenuated by concomitant methotrexate (MTX): <74% MTX+: RR=0.23, 95% CI=0.15 to 0.36; ≥74% MTX+: RR=0.32, 95% CI=0.22 to 0.48. Anti-etanercept antibodies were not detected. Of 936 patients, concomitant MTX or azathioprine/mercaptopurine reduced ADA frequency by 47% (RR=0.53, 95% CI=0.42 to 0.67), particularly when ADA were assessed by RIA (RR=0.36, 95% CI=0.23 to 0.55) compared with ELISA (RR=0.63, 95% CI=0.53 to 0.74). ADA reduces drug response, an effect that can be attenuated by concomitant immunosuppression, which reduces ADA frequency. Drug immunogenicity should be considered for the management of patients receiving biological therapies.

1 June 2014 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SGSandra Garcês
Sandra Garcês
MAMarilia Antunes
Marilia Antunes
EBElizabeth Benito-Garcia
Elizabeth Benito-Garcia
JSJosé Canas da Silva
José Canas da Silva
LALucien Aarden
Lucien Aarden
JDJocelyne Demengeot
Jocelyne Demengeot
Introduction Clinical remission is today the treatment goal for rheumatoid arthritis (RA), which requires fast and assertive therapeutic decisions for a tight control of disease activity. Few objective parameters are available to guide clinical decisions, particularly in switcher patients. We designed a preliminary algorithm introducing immunogenicity assessment in the current approach to patients with RA receiving tumour necrosis factor inhibitors (TNFi). Objective To evaluate the concordance between the new algorithm and current clinical practice, comparing the effectiveness of ‘immunogenicity-based’ versus ‘empirical-based’ switches in a cohort of patients with established RA receiving biologics. Methods EULAR therapeutic response was evaluated in 105 patients with RA (naive or switchers) over one year, through generalised estimation equation (GEE) analyses. Serum drug trough levels were assessed by ELISA and antidrug antibodies (ADAb) by Bridging ELISA. Results During follow-up, 48.6% of patients had therapeutic decisions concordant with the proposed algorithm (Group A), and 51.4% had discordant decisions (Group B). One year after the therapeutic decision, patients from Group A had a higher probability of achieving response (OR=7.91, p<0.001, 95% CI 3.27 to 19.13) and low disease activity (OR=9.77, p<0.001, 95% CI 4.69 to 20.37) than patients in Group B. Conclusions Immunogenicity assessment might help to optimise therapeutic decisions, leading to a better control of disease activity with significantly better clinical outcomes in patients with RA receiving TNFi.

1 July 2015 in Autoimmunity Reviews
Verified
Journal Article
Closed access
MDMaureen Deehan
Maureen Deehan
SGSandra Garcês
Sandra Garcês
DKDaniel Kramer
Daniel Kramer
MBMatthew P. Baker
Matthew P. Baker
DRDorothea Rat
Dorothea Rat
AKArno Kromminga
Arno Kromminga

9 May 2014
Verified
Journal Article
Closed access
JFJoão Eurico Fonseca
João Eurico Fonseca
João GonçalvesJoão Gonçalves
João Gonçalves
FAFilipe Araújo
Filipe Araújo
ICInês Cordeiro
Inês Cordeiro
FTFilipa Teixeira
Filipa Teixeira
SRSociedade Portuguesa De Reumatologia
Sociedade Portuguesa De Reumatologia

5 April 2012
Verified
Journal Article
Closed access
João Eurico FonsecaJoão Eurico Fonseca
João Eurico Fonseca
MBMiguel Bernardes
Miguel Bernardes
HCHelena Canhao
Helena Canhao
MSMaria José Santos
Maria José Santos
AQAlberto Quintal
Alberto Quintal
PRPortuguese Society Of Rheumatology
Portuguese Society Of Rheumatology

1 December 2002
Verified
Journal Article
Closed access
SGSandra Garcês
Sandra Garcês
FAFrancisco Araújo
Francisco Araújo
FRF Rego
F Rego
JSJ L Ducla Soares
J L Ducla Soares
ACA G Palma Carlos
A G Palma Carlos